Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.47 |
| ▸ | CES1 | P23141 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7441502 | 0.88 | CES2 (0.50) | CES2CES1L3MBTL1TP53ALDH1A1 | |
| SCHEMBL7450293 | 0.86 | CES2 (0.51) | CES2CES1TP53ALDH1A1MAPT | |
| SCHEMBL2592 | 0.83 | CES2 (0.43) | CES2CES1SMN1; SMN2L3MBTL1TP53 | |
| SCHEMBL7162802 | 0.81 | NR4A2 (0.48) | SMN1; SMN2L3MBTL1ALDH1A1MAPTKMT2A | |
| SCHEMBL5507382 | 0.80 | NOS3 (0.40) | HPGDMAPTKMT2ARAB9ACYP2C19 | |
| SCHEMBL11784915 | 0.75 | MAPT (0.43) | CES1SMN1; SMN2HPGDL3MBTL1ALOX5 | |
| SCHEMBL8012738 | 0.75 | HDAC1 (0.60) | SMN1; SMN2L3MBTL1ALOX5ALDH1A1MAPT | |
| SCHEMBL2229589 | 0.74 | MAPT (0.41) | CES1SMN1; SMN2HPGDL3MBTL1ALDH1A1 | |
| SCHEMBL5839905 | 0.74 | HTR3E (0.39) | CES2CES1SMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL4704606 | 0.73 | TSHR (0.43) | SMN1; SMN2HPGDL3MBTL1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2378880-A1 | USE OF 5-PYRIDIN-4YL(1,3)THIAZOLE FOR TREATING PHYTOPATHOGENIC FUNGI | BAYER CROPSCIENCE AG (DE) | 2011-10-26 | — | — | EP | claimed |
| WO-2010069494-A1 | USE OF 5-PYRIDIN-4YL(1,3)THIAZOLE FOR TREATING PHYTOPATHOGENIC FUNGI | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2010-06-24 | — | — | WO | claimed |
| EP-1979349-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-10-15 | — | — | EP | claimed |
| WO-2007076035-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-05 | — | — | WO | claimed |
| US-20120288482-A1 | THERAPEUTIC AGENT (Y-39983) FOR CORNEAL ENDOTHELIAL DYSFUNCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-11-15 | — | — | US | disclosed |
| EP-2519237-A1 | THERAPEUTIC AGENT (Y - 39983 ) FOR CORNEAL ENDOTHELIAL DYSFUNCTION | Senju Pharmaceutical Co., Ltd. (JP) | 2012-11-07 | — | — | EP | disclosed |
| EP-1459743-B9 | Agent for prophylaxis and treatment of glaucoma | SENJU PHARMA CO (JP) | 2012-08-01 | — | — | EP | disclosed |
| EP-1391454-B1 | Substituted benzamide compounds with antihypertensive activity | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-05-30 | — | — | EP | disclosed |
| EP-1459742-B9 | Agent for prophylaxis and treatment of asthenopia and pseudomyopia | SENJU PHARMA CO (JP) | 2012-05-02 | — | — | EP | disclosed |
| EP-1459743-B1 | Agent for prophylaxis and treatment of glaucoma | SENJU PHARMA CO (JP) | 2011-10-19 | — | — | EP | disclosed |
| EP-1459742-B1 | Agent for prophylaxis and treatment of asthenopia and pseudomyopia | SENJU PHARMA CO (JP) | 2011-10-12 | — | — | EP | disclosed |
| EP-1295607-B9 | ANTITUMOR EFFECT POTENTIATORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-10-05 | — | — | EP | disclosed |
| EP-0083923-B1 | AMINOACYL-CONTAINING DIPEPTIDE DERIVATIVES USEFUL AS ANTIHYPERTENSIVES | MERCK & CO. INC. (US) | 1988-10-19 | — | — | EP | disclosed |
| US-4774331-A | THIOCYANATION IN PRESENCE OF BORON TRIFLUORIDE | SHIONOGI & CO., LTD. (JP) | 1988-09-27 | — | — | US | disclosed |
| EP-0266849-A1 | Process for introducing a thiocarboxylic ester group at the ortho-position of phenols or phenylamines | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1988-05-11 | — | — | EP | disclosed |
| EP-0257583-A1 | Process for ortho-cyanation of phenols or phenylamines | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1988-03-02 | — | — | EP | disclosed |
| US-4555502-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | MERCK & CO., INC. (US) | 1985-11-26 | — | — | US | disclosed |
| US-4435394-A | 3-Sulfonamido-benzophenonimine derivatives useful for treating virus infections | SHIONOGI & CO., LTD. (JP) | 1984-03-06 | — | — | US | disclosed |
| EP-0083923-A2 | Aminoacyl-containing dipeptide derivatives useful as antihypertensives | MERCK & CO. INC. (US) | 1983-07-20 | — | — | EP | disclosed |
| US-4056544-A | Anthraquinone compounds | BAYER AKTIENGESELLSCHAFT (DT) | 1977-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120288482-A1 | THERAPEUTIC AGENT (Y-39983) FOR CORNEAL ENDOTHELIAL DYSFUNCTION | YES1, VCAM1, EDF1 | CES2 4317/4885CES1 3391/4885SMN1; SMN2 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.